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Abstract
Gene targeting has indicated that Myf5 and MyoD are required for myogenic determination because skeletal myoblasts and myofibers
are missing in mouse embryos lacking both Myf5 and MyoD. To investigate the fate of Myf5:MyoD-deficient myogenic precursor cells
during embryogenesis, we examined the sites of epaxial, hypaxial, and cephalic myogenesis at different developmental stages. In newborn
mice, excessive amounts of adipose tissue were found in the place of muscles whose progenitor cells have undergone long-range migrations
as mesenchymal cells. Analysis of the expression pattern of Myogenin-lacZ transgene and muscle proteins revealed that myogenic precursor
cells were not able to acquire a myogenic fate in the trunk (myotome) nor at sites of MyoD induction in the limb buds. Importantly, the
Myf5-dependent precursors, as defined by Myf5nlacZ-expression, deficient for both Myf5 and MyoD, were observed early in development to
assume nonmuscle fates (e.g., cartilage) and, later in development, to extensively proliferate without cell death. Their fate appeared to
significantly differ from the fate of MyoD-dependent precursors, as defined by 258/2.5lacZ-expression (20 kb enhancer of MyoD), of
which a significant proportion failed to proliferate and underwent apoptosis. Taken together, these data strongly suggest that Myf5 and
MyoD regulatory elements respond differentially in different compartments.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
In vertebrates, four myogenic regulatory factors (MRFs),
belonging to a group of basic helix–loop–helix (bHLH)
transcription factors, are believed to play a critical function
in skeletal muscle cell specification (Weintraub, 1993; Rud-
nicki and Jaenisch, 1995; Megeney and Rudnicki, 1995;
Molkentin and Olson, 1996; Ordahl and Williams, 1998).
Null mutations in Myf5, MyoD, and Mrf4 result in essen-
tially normal patterning of skeletal muscle tissue (Braun et
al., 1992; Rudnicki et al., 1992; Zhang et al., 1995), whereas
mutation in Myogenin causes a substantial reduction in
skeletal muscle tissues (Hasty et al., 1993; Nabeshima et al.,
1993). However, newborn mice carrying null mutations in
both MyoD and Myf5 genes completely lack myoblasts and
skeletal myofibers and die shortly after birth (Rudnicki et
al., 1993). Taken together, these results led to the proposal
that Myf5 and MyoD (primary MRFs) are required for the
determination of skeletal myoblasts, while Myogenin and
MRF4 (secondary MRFs) act later as differentiation factors
(reviewed by Rudnicki and Jaenisch, 1995; Megeney and
Rudnicki, 1995; Kablar and Rudnicki, 2000; Tajbakhsh and
Buckingham, 2000).
Presomitic and somitic multipotential mesodermal cells
in vertebrates give rise to committed myogenic progenitor
cells (also known as premyogenic cells) for the skeletal
muscle of the body (trunk and limbs) and some head mus-
cles. More anterior nonsomitic paraxial and prechordal head
mesoderm are the source of the remaining head muscles
(reviewed by Wachtler and Christ, 1992; Hauschka, 1994;
Christ and Ordahl, 1995). Somites, which initially form as
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epithelial spheres on either side of the neural tube, subse-
quently become compartmentalized into a dorsal epithelial
dermamyotome (dermis and muscle) and a ventral mesen-
chymal sclerotome (vertebral column and ribs). The der-
mamyotome is the source of all skeletal myogenic precursor
cells within the segmented region of the trunk (Ordahl and
Le Douarin, 1992; reviewed by Hauschka, 1994; Christ and
Ordahl, 1995).
Recent work has suggested that muscles of the limbs and
branchial arches were from migratory precursors that are
multipotent prior to MRF expression (Kablar et al., 1999).
This is consistent with previous findings (Tajbakhsh and
Buckingham, 1994) that MRFs are activated after muscle
progenitor cell migration to the limb. Moreover, examina-
tion of E10.5 embryos hybridized with a Pax3 probe reveals
a normal distribution of Pax3-expressing cells migrating
from the dermamyotome into the forelimbs and hindlimbs
in Myf5/:MyoD/ embryos, suggesting that Pax3 induc-
tion and the subsequent migration of myogenic precursors
into the limb are unaffected by the absence of MRF expres-
sion (Kablar et al., 1999). In addition, the presence and
immunoreactivity to proteoglycan antibody (Glant et al.,
1986) of 258/2.5lacZ-expressing cells in the cartilage
primordia of Myf5/:MyoD/ embryos strongly supports
the assertion that muscle progenitor cells are multipotential
in the absence of MRF expression.
Analysis of early muscle differentiation in embryos har-
boring null mutations in either Myf5 or MyoD genes, gen-
erated from transgenic mice in which the bacterial lacZ gene
is under the transcriptional control of a truncated MyoD
gene promoter (MD6.0-lacZ and 258/2.5lacZ), reveals
that Myf5 and MyoD genes are not redundant, but that each
controls the early specification of distinct muscle cell sub-
populations (Kablar et al., 1997, 1998). Based on these
studies, two hypotheses can be considered. In the first,
Myf5-expressing cells constitute a precursor population
from which other cell subpopulations (e.g., MyoD-depen-
dent subpopulation of myoblasts) are later generated (Ka-
blar et al., 1997). In this serial model, myogenic precursor
cells first give rise to a population of cells expressing Myf5,
followed by differentiation of a subset of cells and creation
of a MyoD-dependent subpopulation of myogenic cells (Or-
dahl and Williams, 1998). In the second hypothesis, diver-
sity among myogenic progenitors exists prior to myogenic
specification, resulting in two coexisting Myf5- and MyoD-
dependent myogenic precursor cell subpopulations. To in-
vestigate this phenomenon further, a detailed analysis of
-galactosidase-stained Myf5/:MyoD/ embryos, gen-
erated from Myf5nlacZ mice, was performed. The expression
pattern and fate of Myf5nlacZ-expressing cells deficient for
Myf5 and MyoD was examined and compared with the
expression pattern and fate of mutant 258/2.5lacZ-ex-
pressing cells (20 kb enhancer of MyoD) (Kablar et al.,
1999). Strikingly, the temporal and spatial pattern of Myf5-
lacZ versus MyoD-lacZ expression did not overlap. There-
fore, we conclude that two parallel pathways activate and
maintain Myf5 and MyoD gene expression from the earliest
stages of somite development.
Materials and methods
Interbreeding and collection of embryos
Embryos lacking both Myf5 and MyoD were derived by
a two-generation breeding scheme. First, MyoD/ mice
were bred with Myf5/ mice to generate Myf5/:
MyoD/ mice. Second, Myf5/:MyoD/ mice were in-
terbred to obtain embryos of 9 different genotypes. Trans-
genic Myo1565lacZ mice, generated with 1.565 kb of 5
Myogenin sequence linked to the lacZ transgene, were
kindly provided by E.N. Olson (Cheng et al., 1993). These
transgenic mice were separately bred with mice heterozy-
gous for both the Myf5 and MyoD mutant alleles (Rudnicki
et al., 1993). In addition, the Myf5nlacZ knock-in mice, in
which the nlacZ reporter gene is introduced into the Myf5
locus by homologous recombination (Tajbakhsh et al.,
1996), were used. Myf5nlacZ knock-in mice were also bred
with MyoD/ mice (Rudnicki et al., 1992) to generate
Myf5nlacZ/:MyoD/ mice. Myf5nlacZ/:MyoD/ mice
were interbred to obtain embryos of 9 different genotypes.
Finally, the 258/2.5lacZ transgenic mice, that carry a
construct in which the 258-bp core of the 20-kb MyoD
enhancer is linked to 2.5 kb of MyoD sequence upstream of
the transcription start site upstream of the lacZ gene (Gold-
hamer et al., 1995), were used. These lacZ transgenic mice
were bred in the same way as described for Myf5nlacZ
(Kablar et al., 1999). Embryos and the fetal portion of the
placenta were collected by cesarean section on embryonic
day (E) 10.5, E11.5, and E18.5, and embryos were prepared
for hematoxylin–eosin (HE) or eosin staining, oil red-O
staining, whole-mount -galactosidase staining, immuno-
histochemistry, and whole-mount TUNEL analysis, as de-
scribed below. Genomic DNA was isolated from the fetal
portion of the placenta by using the procedure of Laird et al.
(1991). Embryos were genotyped by Southern analysis
(Sambrook et al., 1989) of placental DNA using Myf5,
MyoD, and lacZ specific probes as described previously
(Rudnicki et al., 1993). Care of animals was in accordance
with institutional guidelines.
-Galactosidase staining
-Galactosidase staining was performed as described by
Kablar et al. (1999). Embryos were fixed 1–2 h (2% para-
formaldehyde, 0.2% glutaraldehyde, 0.1 M phosphate
buffer, pH 7.4, and 2 mM MgCl2), and washed twice for 30
min in solution A (0.1 M phosphate buffer, pH 7.4, 2 mM
MgCl2, 0.1% sodium deoxycholate, 0.2% Nonidet P-40)
and then washed twice, for 30 min in solution B (0.1 M
phosphate buffer, pH 7.4, 2 mM MgCl2, 0.01% sodium
deoxycholate, 0.2% Nonidet P-40). -Galactosidase was
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detected by overnight incubation at 37°C in 1.0 mg/ml
X-gal (5-bromo-4-chloro-3-indolyl--D-galactoside), 5 mM
potassium ferricyanide, and 5 mM potassium ferrocyanide.
Embryos were washed twice for 1 h at room temperature in
phosphate-buffered saline (PBS), post-fixed overnight, de-
hydrated, and stored at 4°C in 70% ethanol. Whole embryos
were photographed in 70% ethanol by using a Zeiss dis-
secting microscope.
Immunohistochemistry
Immunohistochemistry was performed as previously de-
scribed (Kablar et al., 1997, 1998) on paraffin-embedded
4-m sections with mouse monoclonal anti-desmin anti-
body D33 (1:100, DAKO), mouse monoclonal anti-nestin
antibody Rat-401 (1:4, Developmental Studies Hybridoma
Bank), mouse monoclonal anti-myosin heavy chain (MHC)
antibody MF20 (1:10, Bader et al., 1982), mouse monoclo-
nal anti-myocyte nuclear factor (MNF) antibody (1:50,
Garry et al., 1997), mouse monoclonal anti-Proliferating
Cell Nuclear Antigen (PCNA) antibody (1:400, DAKO),
rabbit polyclonal anti-Myf-5 antibody C-20 (1:100, Santa
Cruz), rabbit polyclonal anti-MyoD antibody M-318 (1:50,
Santa Cruz), and rabbit polyclonal anti-Myogenin (myg)
antibody m-225 (1:20, Santa Cruz).
In situ TUNEL analysis
To detect apoptotic nuclei in situ by TUNEL (Gavrieli et
al., 1992), we employed the ApopTag detection system
(Genzyme). Whole embryos (E10.5) or transverse sections
(E10.5; E14.5) were incubated with terminal deoxynucleo-
tydil transferase (TdT enzyme) diluted in the reaction
buffer. The enzyme catalyzes a template-independent addi-
tion of deoxyribonucleotide triphosphate to the 3-OH ends
of double- or single-stranded DNA. The incorporated nu-
cleotides form a random heteropolymer of digoxygenin-11-
dUTP and dATP that has a reaction site for anti-digoxigenin
antibody carrying a conjugated peroxidase enzyme. The
localized peroxidase enzyme was visualized by a chromo-
genic reaction with AEC (3-amino-9-ethylcarbazole,
Sigma). Whole embryos were photographed in 70% ethanol
by using a Zeiss dissecting microscope. For morphometric
analysis of apoptotic nuclei, the embryos were embedded in
paraffin and 10-m serial sections mounted on slides and
counterstained with eosin.
Morphometry
Apoptotic nuclei counts from whole-mount TUNEL-
stained embryos were made in every 10th section corre-
sponding to the forelimb level of an embryo. The data
presented are the actual cell counts multiplied with 10 and
then divided by the total number of sections per region to
yield apoptotic nuclei per section, as described by Kablar
and Rudnicki (1999). Apoptotic nuclei in TUNEL-stained
transverse sections were counted under the magnification of
1000 in 7 randomly chosen microscopic fields with the
area of 9 mm2 per field (Inanlou and B.K., unpublished
data).
The oil red-O-positive lipid droplets were counted in 100
microscopic fields. Each field measured 1 mm2 (total of 1
cm2), and the counts were made at a magnification of
1000.
To evaluate the significance of differences in the number
of lipid droplets or apoptotic nuclei between wild-type and
compound-mutant embryos, the mean and standard error of
the mean (s.e.m.) were calculated for counts of each geno-
type and t tests were performed. All P values are two-sided.
Results
Absence of skeletal muscle and expanded adipose tissue
in newborn mice lacking both Myf5 and MyoD genes
As previously reported by Rudnicki et al. (1993),
Myf5/:MyoD/ newborn mice (E18.5) completely
lack myoblasts and differentiated skeletal muscle in their
head, trunk, and limbs. Previous analysis of early muscle
differentiation in embryos harboring null mutations in
either Myf5 or MyoD genes revealed that Myf5 and MyoD
play unique developmental roles. Myf5 plays a unique
role in development of muscles arising after translocation
of epithelial dermomyotome cells along the edge of the
somite to the subjacent myotome (for example, back and
intercostal muscle precursors by migration). MyoD plays
a unique role in the development of muscles arising from
migratory precursor cells (for example, limb and
branchial arch muscles, tongue, and diaphragm; Kablar et
al., 1997, 1998).
To investigate the fate of myogenic precursor cells that
normally give rise to Myf5-dependent muscles and those
that normally give rise to MyoD-dependent muscle groups,
we analyzed Myf5/:MyoD/ newborn mice at eight
different anatomical locations: external ocular muscles, fa-
cial muscles, tongue, forelimbs, diaphragm, back muscles,
intercostal muscles, and abdominal wall muscles. We found
that in the place of back, intercostal, and abdominal wall
muscles (all epithelial in their origin, i.e., do not form from
migrating muscles progenitors; Ordahl and Williams, 1998),
an excessive amount of adipose tissue was formed (Fig. 1,
and data not shown). The oil red-O staining demonstrated a
4.3 times increase in the number of lipid droplets in the
adipose tissue formed in the intercostal region of double
mutant embryos (i.e., 104  13 in wild-type versus 449 
18 in double mutant, per 1 cm2). Unfortunately, the adipose
tissue did not express the nlacZ transgene and, therefore, we
were unable to demonstrate a coexpression between nlacZ
and oil red-O. It remains possible that the nlacZ-expression
was rapidly downregulated as muscle progenitor cells
change fate to fat. Alternatively, in this case, there is no
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change in cell fate, and our findings simply represent a
physiological expansion of endogenous fat tissue in the
place of the missing muscle tissue.
By contrast, in the place of ocular, facial, and limb
muscle as well as the tongue and the diaphragm (all arise
from long-range migratory myogenic precursor cells; Or-
dahl and Williams, 1998), adipose tissue was not observed
(data not shown). An approximately normal amount of
loose connective tissue was observed in the place of skeletal
muscle in the region of mutant forelimbs (data not shown).
In addition, it was possible to observe cleft palate (pala-
toshisis), somewhat shorter long bones of the limbs and a rib
defect, as previously described for Myf5 null embryos
(Braun et al., 1992).
Absence of Myogenin and muscle proteins in the trunk of
Myf5/:MyoD/ embryos
To investigate whether myogenic precursor cells are able
to differentiate into a small number of myocytes in the
absence of primary MRFs during early stages of embryonic
development, we studied the expression pattern of Myoge-
nin-lacZ trangene in E11.5 embryos that were deficient for
Myf5 and MyoD genes (Fig. 2). In wild-type Myo1565lacZ
transgenic embryos, a strong lacZ expression was detected
in differentiated myocytes throughout the entire myotome
all along the embryonic axis as well as in the extramyotomal
muscle primordia of the ventral neck area, branchial arches,
and forelimbs (Cheng et al., 1993; Fig. 2A). A similar
pattern of expression was also described by Sassoon et al.
(1989) for endogenous Myogenin mRNA. In MyoD/ em-
bryos, myotomal expression of Myogenin-lacZ transgene
was somewhat altered (Fig. 2B) compared with wild-type
embryos. Expression of lacZ appeared uneven in intensity
and the extent of expression particularly at the dorsal edge
varied between myotomes. This corresponds to a reduction
in the amount of differentiated cells in these embryos. Con-
sistent with the expression pattern of Myogenin protein
(Kablar et al., 1997), the Myogenin-lacZ transgene was not
expressed in the forelimbs and branchial arches. In E11.5
Myf-5/ embryos, Myogenin-lacZ expression was greatly
reduced in extent and intensity (Fig. 2C), compared with
wild-type and MyoD/ mice. lacZ expression was only
observed in the dorsal and ventral portions of myotomes
with a large gap present in the central myotomal region.
This corresponds to the aberrant pattern of muscle progen-
itor cells observed previously with the Myf5nlacZ (Tajbakhsh
et al., 1996). Consistent with the expression pattern of
Myogenin protein (Kablar et al., 1997), lacZ transgene was
found in the forelimbs and branchial arches. In Myf5/:
MyoD/ embryos, Myogenin-lacZ expression was ob-
served (Fig. 2D). No ectopic expression was detected in any
of the genotypes studied for this transgene (Fig. 2A–D).
Therefore, in the Myf5:MyoD mutants, myogenic precursor
cells do not acquire a myoblast phenotype.
To investigate further if any myogenic precursor cells
form and differentiate into skeletal myoblasts in the myo-
tomes of Myf5/:MyoD/ embryos, we employed immu-
nohistochemistry on transverse section of wild-type and
mutant embryos at E11.5 (Fig. 3). A panel of antibodies
reactive with proteins also expressed in myogenic precursor
cells (Myf5, MyoD, and MNF; Garry et al., 1997), in myo-
blasts (Myogenin, nestin, and desmin), and in differentiated
myotubes (MHC) was employed. Desmin and nestin are
intermediate filaments expressed in both proliferating myo-
blasts and newly formed differentiating myocytes, whereas
MHC is expressed exclusively in terminally differentiated
myotubes and myofibers (Bischoff, 1994; Hauschka, 1994).
Transverse sections of E11.5 wild-type embryos at the
level of forelimbs stained with anti-Myf5, anti-MyoD, and
anti-MNF antibody revealed presence of myogenic precur-
sor cells in the region of the myotome (Fig. 3A, C, and E).
Adjacent sections stained with anti-myg, anti-nestin, and
anti-desmin antibody revealed presence of myoblasts and
differentiated myocytes in the myotome at the forelimb
level (Fig. 3G, I, and K). Sections stained with anti-MHC
antibody revealed presence of terminally differentiated
myotubes and myofibers in the region of the myotome (Fig.
3M). Transverse sections of E11.5 Myf5/:MyoD/ em-
bryos at the level of forelimbs did not stain with anti-Myf5,
anti-MyoD, and anti-MNF antibody, revealing absence of
Myf5-, MyoD- (and correct genotyping), or MNF-express-
ing myogenic precursor cells in the region of the myotome
(Fig. 3B, D, and F). Companion sections did not stain with
anti-myg, anti-nestin, and anti-desmin antibody, revealing
Fig. 1. Newborn (E18.5) Myf5/:MyoD/ embryos lack all skeletal
muscle and have excess of adipose tissue. Transverse sections of E18.5
wild-type (A, C) and Myf5/:MyoD/ embryos (B, D) stained with HE
(A, B) and oil red-O (C, D) reveal that, in the place of intercostal muscles
(m in A; arrowheads in C show normal amount of lipid droplets in the
skeletal muscle tissue), an excessive amount of adipose tissue is visible in
mutant embryos only (a, in B; arrowheads in D show lipid droplets whose
number is significantly increased in the tissue replacing intercostal muscle).
Abbreviations: a, adipose tissue; 1, lung, m, intercostal skeletal muscle, r,
rib primordium (note that mutant embryos have a rib defect). Magnifica-
tion, 100  (A, B), 1000  (C, D).
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absence of myoblasts and differentiated myocytes in the
myotome at the forelimb level (Fig. 3H, J, and L). Sections
that did not stain with anti-MHC antibody revealed absence
of terminally differentiated myotubes and myofibers in the
region of the myotome (Fig. 3N). Sections of both wild-type
and mutant embryos stained with anti-MNF and anti-nestin
also stained neuroepithelial derivatives (Fig. 3E, F, I, and J).
The sections made at E10.5, as well as sections in the
forelimbs, gave the same results (data not shown).
Therefore, we conclude that, in these Myf5:MyoD mu-
tants, myogenic precursor cells can not undergo their nor-
mal developmental program that leads to the acquisition of
a myogenic fate. Presumably, these precursor cells remain
either developmentally arrested, undergo programmed cell
death, or change their fate.
Increased apoptosis in the somites and forelimbs of
Myf5/:MyoD/ embryos
To investigate whether myogenic precursor cells un-
dergo programmed cell death in the absence of primary
MRFs, we performed whole-mount in situ TUNEL analysis
on wild-type (Fig. 4A–D) and Myf5/:MyoD/ (Fig.
4E–H) E10.5 embryos. This analysis revealed increased
levels of programmed cell death in both the somite and the
forelimbs. Morphometric analysis of serial transverse sec-
tions revealed a statistically significant (P  0.001) differ-
ence between the number of apoptotic nuclei in wild-type
and double mutant somite (19  5 per section in wild-type
embryos and 32  7 per section in mutant embryos; com-
pare Fig. 4C and Fig. 4G) and limbs (14  6 per section in
wild-type embryos and 27  5 per section in mutant em-
bryos; compare Fig. 4D and Fig. 4H). High level of apo-
ptosis was observed in apical forelimb bud ridge of both
genotypes (Fig. 4D and H). In the wild-type E10.5 embryo,
the number of cells that express MyoD is 138  19 per
section.
To determine whether apoptosis affected differently
lacZ-expressing cells in Myf5nlacZ/nlacZ:MyoD/ embryos
in comparison with Myf5/:MyoD/ embryos expressing
258/ 2.5lacZ (20 kb enhancer of MyoD), we performed
TUNEL analysis on transverse sections. In both the myo-
tome and the forelimbs, the number of apoptotic cells (co-
expressed with lacZ) was significantly higher (P 0.001) in
E10.5 Myf5nlacZ/nlacZ:MyoD/ embryos in comparison
with the Myf5nlacZ/ control (Fig. 4I and J, the myotome, 12
 3 per section in control embryos and 27  4 per section
in mutant embryos; Fig. 4K and L, the forelimbs, 11 7 per
Fig. 2. The expression of Myogenin-lacZ transgene in E11.5 Myf5/:
MyoD/ embryos is totally abolished. Wild-type Myo1565lacZ transgenic
embryos (A) have a strong lacZ expression throughout the entire myotome,
the ventral neck area, branchial arches (arrowhead in A), and forelimbs
(arrow in A). In E11.5 MyoD/ embryos, myotomal expression of Myo-
genin-lacZ transgene appears uneven in intensity and the extent at the
dorsal edge (red arrows in B). lacZ transgene is not expressed in the
forelimbs (black arrow in B) and branchial arches (arrowhead in B). In
E11.5 Myf5/ embryos, lacZ expression is greatly reduced in extent and
intensity (C) and is only observed in the dorsal and ventral portions of
myotomes with a large gap present in the central myotomal region (red
arrows in C). lacZ transgene is found in the forelimbs (black arrow in C)
and branchial arches (arrowhead in C). In Myf5/:MyoD/ embryos, no
Myo1565lacZ expression is observed (D). No ectopic expression is de-
tected in any of the genotypes studied for this transgene (A–D).
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section in control embryos and 23 5 per section in mutant
embryos). No difference (in comparison to control, P 
0.05) was found when the same analysis was performed on
wild-type (control) and Myf5/:MyoD/ embryos ex-
pressing 258/2.5lacZ (the myotome, 6  3 per section in
control embryos and 3  4 per section in mutant embryos;
the forelimbs, 4 7 per section in control embryos and 6
5 per section in mutant embryos).
Therefore, we conclude that, in the absence of Myf5 and
MyoD, muscle progenitor cells undergo programmed cell
death from early stages of development.
Muscle progenitor cell fate and somite
compartmentalization are affected in Myf5:MyoD mutants
To study muscle progenitor cell fate and the process of
somite compartmentalization, we employed the Myf5nlacZ
knock-in mice, in which the nlacZ reporter gene is intro-
duced into the Myf5 locus by homologous recombination
(Tajbakhsh et al., 1996). Previously, it was shown that
nlacZ-expressing muscle progenitor cells are present in the
dermomyotome of Myf5 null embryos, where they undergo
aberrant migration and are found in dermal precursors to
express Dermo-1 and in sclerotome to coexpress scleraxis
(Tajbakhsh et al., 1996). Consistently, in Myf5nlacZ/nlacZ:
MyoD/ embryos, muscle progenitors that have activated
Myf5 are present, but the pattern of -galactosidase staining
in mutant embryos (Figs. 5B, D, F, H, and J and 6B, D, F,
H, J, and L) is substantially different from the heterozygous
pattern (Figs. 5A, C, E, G, and I, and 6A, C, E, G, I, and K).
At earlier stages (E11.5 and E12.5), the pattern of -ga-
lactosidase staining between heterozygous and mutant em-
bryos is not different due to the shape of the dermomyotome
(Fig. 5A–D, arrowheads in B), but is due to the fact that
progenitor cells are developmentally arrested and are re-
tained outside and adjacent to the dorsal and ventral der-
momyotome lips. In transverse tissue sections (E12.5), it
was possible to note that, like in the heterozygous myo-
tomes (Fig. 6A and E, m), nlacZ-expressing cells of mutant
embryos delaminated from the dermomyotome and lost
their columnar shape to become mesenchymal, at both the
level of the limbs (Fig. 6B, m) and at the level of the tail
(Fig. 6F, m). However, some nlacZ-expressing mutant cells
were found dorsally, in the columnar dermatome (Fig. 6F,
d) and ventrally in the sclerotome (Fig. 6F, s). Heterozygous
dermatome (Fig. 6E, d) and sclerotome (Fig. 6E, s) did not
contain nlacZ-expressing cells. Occasionally, nlacZ-ex-
pressing cells were also found in the dermis of mutant
forelimbs (Fig. 6D, arrowhead). At later developmental
Fig. 3. Transverse sections of E11.5 wild-type (A, C, E, G, I, K, M) and
Myf5/:MyoD/ (B, D, F, H, J, L, N) embryos at the level of forelimbs,
stained with anti-Myf5 (A, B), anti-MyoD (C, D), anti-MNF (E, F),
anti-Myogenin (G, H), anti-nestin (I, J), anti-desmin (K, L), and anti-MHC
(M, N) antibody. No antibody marks the region of mutant myotome
(arrows in B, D, F, H, J, L, N), while the expected staining pattern is visible
in the wild-type myotome (arrows in A, C, E, G, I, K, M). Abbreviations:
drg, dorsal root ganglia. Magnification, 200.
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ages (E13.5–E15.5), the pattern of -galactosidase staining
between heterozygous and mutant embryos differed signif-
icantly. While the staining in heterozygous embryos was
spreading at the sites of skeletal muscle development (Fig.
5E, G, and I), the pattern of -galactosidase expression in
mutant embryos remained restricted first to the dorsal- and
ventral-most myotomes and to the limbs (Fig. 5F), followed
by its further restriction to the dorsal dermomyotomal re-
gions and limbs (Fig. 5H and J).
To further our understanding of muscle progenitor cell
fate in Myf5:MyoD mutants, we performed immunohisto-
Fig. 4. Muscle progenitor cells undergo programmed cell death from early
developmental stages in the absence of Myf5 and MyoD. Whole-mount
TUNEL detection of apoptosis is performed in E10.5 wild-type (A–D) and
Myf5/:MyoD/ (E–H) embryos. In both the dermomyotome (arrows in C
and G) and the forelimbs (arrows in D and H), a significantly elevated
occurrence of programmed cell death is observed in Myf5/:MyoD/ em-
bryos. Morphometric analysis of serial transverse sections reveals a statisti-
cally significant difference between the number of apoptotic nuclei in wild-
type and mutant dermomyotome and limbs (see Results). High level of
apoptosis is observed in apical forelimb bud ridge of both genotypes (arrow-
heads in D and H). TUNEL analysis on transverse sections is performed to
assess apoptosis in E10.5 Myf5nlacZ/nlacZ:MyoD/ embryos (J, L) in compar-
ison with the Myf5nlacZ/ control (I, K). In both the myotome (I, J) and the
forelimbs (K, L), the number of apoptotic cells (coexpressed with lacZ,
arrowheads in I, J) was significantly higher in E10.5 Myf5nlacZ/nlacZ:MyoD/
embryos in comparison with the control (see Results). Abbreviations: drg,
dorsal root ganglia; nt, neural tube. Magnification (C, D, G, H), 200.
Fig. 5. The expression pattern of Myf5nlacZ transgene in heterozygous
E11.5 (A), E12.5 (C), E13.5 (E), E14.5 (G), E15.5 (I), and Myf5nlacZ/nlacZ:
MyoD/ E11.5 (B), E12.5 (D), E13.5 (F), E14.5 (H), E15.5 (J) embryos,
as revealed by whole-mount -galactosidase staining. At earlier stages
(E11.5 and E12.5; A–D), the pattern of -galactosidase staining between
heterozygous and mutant embryos is distinguished by the aberrant pattern
of muscle progenitor cell accumulation (arrowheads in B). At later devel-
opmental ages (E13.5–E15.5; E–J), the staining in heterozygous embryos
extends to the sites of skeletal muscle development (E, G, I). By contrast,
the mutant pattern of -galactosidase expression remains restricted to the
dorsal and ventral tips of the somites and to the limbs (F), followed by its
further restriction to the dorsal myotomal tips and limbs (H, J).
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chemistry against anti-proliferating cell nuclear antigen
(PCNA) antibody. PCNA functions as a cofactor for DNA
polymerase delta in S-phase of the cell cycle. In transverse
forelimb sections from Myf5nlacZ heterozygous (Fig. 7A)
and 258/2.5lacZ (20 kb enhancer of MyoD) (Fig. 7C)
E14.5 embryos, it was not possible to observe expression of
PCNA in the nuclei expressing lacZ (Fig. 7A and C, arrow-
heads). Surprisingly, immunostaining of transverse forelimb
sections from Myf5nlacZ/nlacZ:MyoD/ mutant (Fig. 7B)
E14.5 embryos revealed that lacZ-expressing cells were
also PCNA-positive (Fig. 7B, arrowheads), whereas in 258/
2.5lacZ double mutant (Myf5/:MyoD/) embryos, co-
expression of PCNA and -galactosidase was a very rare
observation (Fig. 7D, arrowheads).
Previously, double labeling of matched wild-type and
compound mutant sections of embryos with -galactosidase
and in situ detection of apoptosis (TUNEL) revealed a
massive programmed cell death of cells stained with 258/
2.5lacZ in double mutant embryos (Kablar et al., 1999).
By contrast, TUNEL detection in Myf5nlacZ/nlacZ:MyoD/
E14.5 embryos revealed that -galactosidase-expressing
cells were not undergoing programmed cell death (Fig. 7F)
and that a different group of cells, not expressing Myf5nlacZ,
was undergoing apoptosis in double mutant forelimbs (Fig.
7F, arrowheads). Consistently, no apoptosis was observed
in cells expressing Myf5nlacZ/ E14.5 embryos (Fig. 7E).
Taken together, these results indicate that in the absence
of Myf5 and MyoD muscle progenitor cells delaminate
from the dermomyotome to become mesenchymal. These
cells encounter multiple cell fate decisions: they remain
multipotent and affect somite compartmentalization in the
trunk, remain highly proliferative and developmentally ar-
rested, or change fate into (dermis) or cartilage or undergo
programmed cell death.
Discussion
Mounting evidence supports the notion that Myf5 and
MyoD play unique roles in the development of epaxial
(originating in the dorsomedial half of the somite, e.g., back
muscles) and hypaxial (originating in the ventrolateral half
of the somite, e.g., limb and body wall muscles) muscula-
ture, respectively (Kablar et al., 1997, 1998; Ordahl and
Williams, 1998). Analysis of Myf5/:MyoD/ newborn
mice revealed that, in the place of back, intercostal, and
abdominal wall muscles, all arising from short-range mi-
grations (Ordahl and Williams, 1998; Tajbakhsh and Buck-
ingham, 2000), an excessive amount of adipose tissue was
formed. By contrast, in the place of ocular, facial, limb
muscle, tongue, and diaphragm, arising from migratory
mesenchymal myogenic progenitor cells (Ordahl and Wil-
liams, 1998), adipose tissue was not found. Interestingly,
expression of lacZ in ribs and nonmuscle cells is observed
in Myf5nlacZ knock in mice in the absence of Myf5 (Taj-
bakhsh et al., 1996), as well as in the absence of both Myf5
and MyoD. In addition, some cells of the Myf5/:
MyoD/ cartilage primordia coexpress MyoD-lacZ (258/
2.5lacZ) and anti-fetal cartilage proteoglycan protein (Ka-
blar et al., 1999), suggesting that myogenic precursor cells
change not only their position, but also their identity in a
mutant embryo. In the present study, we were not able to
demonstrate colocalization of the adipose marker and -ga-
lactosidase. Interestingly, we note that the expansion in
adipose tissue was observed only in the trunk, but not in the
regions where migratory muscle cell progenitors give rise to
skeletal muscle.
Myogenic precursor cells initially arise in the epaxial
epithelial somite, followed by a substantial contribution
mainly from epaxial and hypaxial edges of the dermomyo-
tome (Tajbakhsh and Spo¨rle, 1998; Tajbakhsh and Buck-
ingham, 2000). As mentioned previously, Myf5/:
MyoD/ E18.5 embryos and newborns lack all skeletal
muscle (Rudnicki et al., 1993), indicating that Myf5 and
MyoD are key regulators of myogenic determination. How-
ever, it remained unclear whether the precursor myoblast
population did not form, did not differentiate, or just did not
survive in the Myf5/:MyoD/ embryo. It was later
shown that, prior to MyoD activation, muscle progenitor
Fig. 6. The expression pattern of Myf5nlacZ transgene in Myf5nlacZ/ E12.5 (A, C, E) and Myf5nlacZ/nlacZ:MyoD/ E12.5 (B, D, F) embryos, in transverse
sections counterstained with eosin. nlacZ-expressing cells of mutant embryos delaminate from the dermomyotome (d in F) and lose their columnar shape to
become mesenchymal myotome at the level of the limbs (m in B) and at the level of the tail (m in F). In addition, some nlacZ-expressing mutant cells are
found in the dermomyotome (d in F) and sclerotome (s in F). Heterozygous dermomyotome (d in E) and sclerotome (s in E) does not contain nlacZ-expressing
cells. nlacZ-expressing cells are also found in the dermis of mutant forelimbs (D, arrowhead). Please note that the same letters are used for labeling of the
corresponding regions of the myotome (m) and the dermomyotome (d) in the double mutant embryos, although double mutant embryos do not form the
myotome and the dermomyotome. Abbreviations: d, dermamyotome; drg, dorsal root ganglia; h, humeral primordium; m, myotome; s, sclerotome; sc, spinal
cord. Magnification, 400.
Fig. 7. Immunostaining against anti-PCNA antibody (A–D) and in situ detection of apoptosis (TUNEL) (E, F) in transverse forelimb sections from E14.5
Myf5nlacZ/ (A, E), E14.5 258/-2.5lacZ wild-type (C), E14.5 258/2.5lacZ double mutant (Myf5/:MyoD/) (D), and E14.5 Myf5nlacZ/nlacZ:MyoD/ (B,
F) embryos. lacZ-expressing cells strongly coexpress PCNA in Myf5nlacZ/nlacZ:MyoD/ forelimb (arrowheads in B and in the inset: the X-gal staining appears
as a dark blue-turquoise rim around the nuclear red-brown immunostaining), but not in the Myf5nlacZ heterozygous (A, arrowheads) or 258/2.5lacZ wild-type
forelimb (C, arrowheads). In 258/ 2.5lacZ double mutant embryos, coexpression of PCNA and -galactosidase was a very rare observation (D, arrowheads).
In both heterozygous and double mutant forelimbs nlacZ-expressing cells are not undergoing programmed cell death (E, F). However, a group of cells that
does not express nlacZ is undergoing apoptosis in double mutant forelimb only (arrowheads in F and in the inset: the X-gal staining does not appear as a
dark blue-turquoise rim around the nuclear red-brown immunostaining). Note that numerous 258/2.5lacZ-expressing nuclei appear apoptotic in double
mutant forelimbs (D, arrows). Magnification, 400, 1000 (insets).
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cells were present and survive in Myf5nlacZ/nlacZ embryos
(Tajbakhsh et al., 1996, 1997). We recently investigated the
expression patterns of MyoD-lacZ transgenes in Myf5/:
MyoD/ embryos and observed that Myf5- and MyoD-
deficient presumptive muscle progenitor cells expressing
-galactosidase form and survive during several embryonic
days in the absence of both primary MRFs (Kablar et al.,
1999). To investigate whether myogenic precursor cells
could acquire a myogenic fate during early stages of
Myf5/:MyoD/ embryonic development, we studied the
expression pattern of Myogenin-lacZ transgene and a panel
of antibodies reactive with proteins present in either myo-
genic precursor cells (Myf5, MyoD, and MNF; Garry et al.,
1997), myoblasts (Myogenin, nestin, and desmin), or dif-
ferentiated myotubes (MHC). Consistently, we did not de-
tect any of these markers in somites of Myf5/:MyoD/
E10.5 and E11.5 embryos, and we concluded that, in these
double mutants, myogenic precursor cells could not un-
dergo their normal developmental program that led to the
acquisition of a myogenic fate.
We have recently reported an observation that the
20-kb MyoD enhancer activates expression in newly
formed somites and limb buds in compound mutant em-
bryos, suggesting that myogenic determination occurs inde-
pendently in somites and limb buds (Kablar et al., 1999;
Tajbakhsh and Buckingham, 2000). In addition, we have
found that Pax3 induction and the subsequent migration of
myogenic precursors into the limb are unaffected by the
absence of MRF expression (Kablar et al., 1999). However,
Myf5/:MyoD/ embryonic forelimb buds did not stain
with antibodies reactive with proteins present in myoblasts
(Myogenin and desmin) or differentiated myotubes (MHC),
and we concluded that, in these Myf5:MyoD mutants, myo-
genic precursor cells could not acquire myogenic fate even
at the site of the de novo induction of MyoD transcription
during development. We note, however, that in the
Myf5nlacZ/nlacZ null, Mrf4 expression is compromised due to
the insertion of foreign sequences in the Myf5 locus (Taj-
bakhsh, 2002; S.T. and Buckingham, unpublished data).
Therefore, we cannot exclude a myogenic role for Mrf4 in
the absence of Myf5 and MyoD.
The precursor cells found in Myf5/:MyoD/ em-
bryos (Kablar et al., 1998, 1999; B.K. and M.A.R., unpub-
lished observation) could remain developmentally arrested,
undergo programmed cell death, or change their fate (Taj-
bakhsh et al., 1996; Kablar et al., 1999). Recently, reported
analysis reveals that MyoD-lacZ-expressing cells at the ear-
lier embryonic ages (between E10.5 and E12.5) show sim-
ilarly low apoptosis in the forelimbs of both wild-type and
Myf5/:MyoD/ embryos (Kablar et al., 1999). In addi-
tion, double-labeling of matched wild-type and Myf5/:
MyoD/ sections of E13.5 embryos with -galactosidase
and TUNEL reveals increased levels of programmed cell
death of cells stained with 258/2.5lacZ in mutant em-
bryos, suggesting that by E13.5, many of these lacZ-ex-
pressing cells are eliminated by programmed cell death
(Kablar et al., 1999). However, the more accurate whole-
mount in situ TUNEL detection revealed that, at both sites
of myogenic determination, the dermomyotome and the
forelimbs, increased levels of programmed cell death was
observed in Myf5/:MyoD/ E10.5 embryos. Taken to-
gether, it appears that, from the early stages of muscle
development, apoptosis (on E10.5) eliminates a portion of
myogenic precursor cells at both sites of myogenic deter-
mination, the dermomyotome and the forelimbs. Moreover,
it appears that, at this early stage, apoptosis partially elim-
inates Myf5-positive cells in the absence of Myf5 and
MyoD, while at later stages (on E13.5), apoptosis eliminates
MyoD-lacZ-expressing myogenic precursor cells. In sup-
port of this hypothesis are findings that Myf5nlacZ-express-
ing cells in the forelimbs of E14.5 compound-mutant em-
bryos did not undergo apoptosis and instead coexpressed
PCNA, whereas some adjacent cells which may be MyoD-
dependent at this stage were destined to die. These findings
highlight the differential roles of Myf5- and MyoD-express-
ing cells. At late stages, it is possible that Myf5 downregu-
lation and continued MyoD expression represent a more
“downstream” myogenic cell which would subsequently
undergo apoptosis. The susceptibility of the cell to undergo
apoptosis my also be related to the signals received by that
cell, as reflected by the differential activation of the Myf5
and MyoD regulatory elements.
Analysis of muscle development in embryos harboring
null mutations in either Myf5 or MyoD genes, reveals that
Myf5 and MyoD are not redundant, but that each controls
the early determination of a distinct muscle cell compart-
ment (Kablar et al., 1997, 1998). Based on these studies,
diversity among myogenic precursor cells is hypothesized
to exist from early stages of embryonic development, re-
sulting in two coexisting Myf5- and MyoD-dependent myo-
genic precursor cell lineages. Detailed analysis of 258/
2.5lacZ (20 kb enhancer of MyoD) embryos (Kablar et
al., 1999) and the analysis of Myf5nlacZ embryos (Tajbakhsh
et al., 1996) indicated that, in the absence of both Myf5 and
MyoD, muscle progenitor cells indeed existed, delaminated
from the dermamyotome to become mesenchymal and re-
mained multipotential.
During later developmental stages, striking differences in
fate were found between 258/2.5lacZ- and Myf5nlacZ-ex-
pressing cells in double mutant background. The MyoD-
lacZ-expressing cells were found to undergo cell death from
E13.5, while Myf5nlacZ-expressing cells continued to prolif-
erate (e.g., coexpress PCNA and -galactosidase) and there-
fore remained developmentally arrested (on E14.5). One
possibility is that separate lineages activate these genes
(Braun and Arnold, 1996). For instance, using targeted
inactivation of Myf5 and MyoD, it was shown that the two
MRFs are not expressed in the same muscle precursor cell
in an in vitro embryonic stem (ES) derived system, and that
their expression pattern determines different muscle cell
lineages originating from different myogenic precursor cell
populations. Another interpretation is that different signals
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preferentially activate (Cossu et al., 1996; Tajbakhsh et al.,
1998) and maintain their expression. For instance, by em-
ploying cultures of paraxial mesoderm with a variety of
adjacent structures, it was demonstrated that the neural tube
activates myogenesis through a Myf5-dependent pathway,
whereas the dorsal ectoderm activates myogenesis through a
MyoD-dependent pathway. To distinguish between these
possibilities, one would need to generate a MyoD knock-in
mouse expressing a transgene other than lacZ (e.g., alkaline
phosphatase), that can be subsequently bred with the
Myf5nlacZ knock-in mouse in order to obtain embryos ex-
pressing both transgenes.
In conclusion, we show in vivo that myogenic precursor
cells are not capable of acquiring a myogenic phenotype in
these Myf5:MyoD mutants, even at later stages. Instead,
these cells can remain either developmentally arrested for
an extended period, change their fate, or undergo pro-
grammed cell death.
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